Tags

Type your tag names separated by a space and hit enter

Human Biofield Therapy and the Growth of Mouse Lung Carcinoma.
Integr Cancer Ther 2019 Jan-Dec; 18:1534735419840797IC

Abstract

Biofield therapies have gained popularity and are being explored as possible treatments for cancer. In some cases, devices have been developed that mimic the electromagnetic fields that are emitted from people delivering biofield therapies. However, there is limited research examining if humans could potentially inhibit the proliferation of cancer cells and suppress tumor growth through modification of inflammation and the immune system. We found that human NSCLC A549 lung cancer cells exposed to Sean L. Harribance, a purported healer, showed reduced viability and downregulation of pAkt. We further observed that the experimental exposure slowed growth of mouse Lewis lung carcinoma evidenced by significantly smaller tumor volume in the experimental mice (274.3 ± 188.9 mm3) than that of control mice (740.5 ± 460.2 mm3; P < .05). Exposure to the experimental condition markedly reduced tumoral expression of pS6, a cytosolic marker of cell proliferation, by 45% compared with that of the control group. Results of reversed phase proteomic array suggested that the experimental exposure downregulated the PD-L1 expression in the tumor tissues. Similarly, the serum levels of cytokines, especially MCP-1, were significantly reduced in the experimental group (P < .05). Furthermore, TILs profiling showed that CD8+/CD4- immune cell population was increased by almost 2-fold in the experimental condition whereas the number of intratumoral CD25+/CD4+ (T-reg cells) and CD68+ macrophages were 84% and 33%, respectively, lower than that of the control group. Together, these findings suggest that exposure to purported biofields from a human is capable of suppressing tumor growth, which might be in part mediated through modification of the tumor microenvironment, immune function, and anti-inflammatory activity in our mouse lung tumor model.

Authors+Show Affiliations

1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA.1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA.1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA.1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA.1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA.1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA.2 Sean Harribance Institute for Parapsychology, Inc., Sugarland, TX, USA.1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

30947564

Citation

Yang, Peiying, et al. "Human Biofield Therapy and the Growth of Mouse Lung Carcinoma." Integrative Cancer Therapies, vol. 18, 2019, p. 1534735419840797.
Yang P, Jiang Y, Rhea PR, et al. Human Biofield Therapy and the Growth of Mouse Lung Carcinoma. Integr Cancer Ther. 2019;18:1534735419840797.
Yang, P., Jiang, Y., Rhea, P. R., Coway, T., Chen, D., Gagea, M., ... Cohen, L. (2019). Human Biofield Therapy and the Growth of Mouse Lung Carcinoma. Integrative Cancer Therapies, 18, p. 1534735419840797. doi:10.1177/1534735419840797.
Yang P, et al. Human Biofield Therapy and the Growth of Mouse Lung Carcinoma. Integr Cancer Ther. 2019;18:1534735419840797. PubMed PMID: 30947564.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Human Biofield Therapy and the Growth of Mouse Lung Carcinoma. AU - Yang,Peiying, AU - Jiang,Yan, AU - Rhea,Patrea R, AU - Coway,Tara, AU - Chen,Dongmei, AU - Gagea,Mihai, AU - Harribance,Sean L, AU - Cohen,Lorenzo, PY - 2019/4/6/entrez PY - 2019/4/6/pubmed PY - 2019/4/6/medline KW - Lewis lung carcinoma KW - PD-L1 KW - biofield KW - immune modulation SP - 1534735419840797 EP - 1534735419840797 JF - Integrative cancer therapies JO - Integr Cancer Ther VL - 18 N2 - Biofield therapies have gained popularity and are being explored as possible treatments for cancer. In some cases, devices have been developed that mimic the electromagnetic fields that are emitted from people delivering biofield therapies. However, there is limited research examining if humans could potentially inhibit the proliferation of cancer cells and suppress tumor growth through modification of inflammation and the immune system. We found that human NSCLC A549 lung cancer cells exposed to Sean L. Harribance, a purported healer, showed reduced viability and downregulation of pAkt. We further observed that the experimental exposure slowed growth of mouse Lewis lung carcinoma evidenced by significantly smaller tumor volume in the experimental mice (274.3 ± 188.9 mm3) than that of control mice (740.5 ± 460.2 mm3; P < .05). Exposure to the experimental condition markedly reduced tumoral expression of pS6, a cytosolic marker of cell proliferation, by 45% compared with that of the control group. Results of reversed phase proteomic array suggested that the experimental exposure downregulated the PD-L1 expression in the tumor tissues. Similarly, the serum levels of cytokines, especially MCP-1, were significantly reduced in the experimental group (P < .05). Furthermore, TILs profiling showed that CD8+/CD4- immune cell population was increased by almost 2-fold in the experimental condition whereas the number of intratumoral CD25+/CD4+ (T-reg cells) and CD68+ macrophages were 84% and 33%, respectively, lower than that of the control group. Together, these findings suggest that exposure to purported biofields from a human is capable of suppressing tumor growth, which might be in part mediated through modification of the tumor microenvironment, immune function, and anti-inflammatory activity in our mouse lung tumor model. SN - 1552-695X UR - https://www.unboundmedicine.com/medline/citation/30947564/Human_Biofield_Therapy_and_the_Growth_of_Mouse_Lung_Carcinoma L2 - http://journals.sagepub.com/doi/full/10.1177/1534735419840797?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -